Adult Dosing

Claudication

• Usual dose: 400 mg PO tid with meals

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Intermittent claudication on the basis of chronic occlusive arterial disease of the limbs
• Improve function and symptoms of peripheral vascular disease

• Hypersensitivity to any of the ingredients of the product
• Recent cerebral hemorrhage
• Recent retinal hemorrhage
• Methylxanthine intolerance

• N/A

Renal Dose Adjustment (Based on CrCl)

• >50 mL/minute: Give q8-12 hrs
• 10-50 mL/minute: Give q12-24h
• <10 mL/minute: Give q24h

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Angina, hypotension, and arrhythmia have been reported with the use of pentoxifylline
• Monitor for coagulation defects for risk of bleeding
• Monitor prothrombin time in patients who are receiving warfarin. patients with risk factors of hemorrhage should have periodic examinations for bleeding including hematocrit and/or hemoglobin

Pentoxil, Trental interacts with :

	Elixophyllin
	Theo-24
	Theochron
	Theolair
	Theophylline

Pregnancy Category:C

Breastfeeding: Pentoxifylline is poorly excreted into breastmilk. It would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 April 2011). Manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.

• CV: Arrhythmias, Angina, hypotension
• CNS: Dizziness, drowsiness, headache, seizures, depression
• GI: Dyspepsia, nausea, vomiting, cholestasis
• HEMA: Aplastic Anemia
• MISC: Edema, increased LFTs, jaundice
• HYPERSENSITIVITY: Immune system disorders - anaphylactic reaction, anaphylactoid reaction, anaphylactic shock

• Hemorrheologic agent; decreases blood viscosity and improves blood flow by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity
• Metabolized in erythrocytes and liver; CYP450: Unknown
• Excreted in urine and feces (<4%)
• Half-life
• Parent drug: 0.4-0.8 hrs
• Metabolites: 1-1.6 hrs

US Trade Name(s)

• Pentoxil
• Trental

US Availability

pentoxifylline (generic)

• ETABS: 400 mg

Pentoxil

• ETABS: 400 mg

Trental

• ETABS: 400 mg

Canadian Trade Name(s)

• Trental

Canadian Availability

pentoxifylline (generic)

• ETABS: 400 mg

Trental

• ETABS: 400 mg

UK Trade Name(s)

• Trental

UK Availability

Trental

• ETABS: 400 mg

Australian Trade Name(s)

• Trental-400

Australian Availability

Trental-400

• ETABS: 400 mg

Hematology/Oncology

Antihemorrhagic Agents

Pricing data from www.DrugStore.com in U.S.A.

• TRENtal 400 MG TBCR [Bottle] (SANOFI-AVENTIS U.S.)
  60 mg = $79.99
  180 mg = $219.96
• Pentoxifylline CR 400 MG TBCR [Bottle] (TEVA PHARMACEUTICALS USA)
  100 mg = $32.99
  300 mg = $72.98

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Pentoxifylline 400 MG Extended Release Tablet (Mylan Pharmaceuticals Inc.)
• Pentoxifylline 400 MG Extended Release Tablet (NCS HealthCare of KY, Inc dba Vangard Labs)
• Pentoxifylline 400 MG Extended Release Tablet (Physicians Total Care, Inc.)
• Pentoxifylline 400 MG Extended Release Tablet (State of Florida DOH Central Pharmacy)
• Pentoxifylline 400 MG Extended Release Tablet (TEVA PHARMACEUTICALS USA)
• Pentoxil 400 MG Extended Release Tablet (UPSHER-SMITH LABORATORIES, INC.)
• Trental 400 MG Extended Release Tablet (Sanofi-Aventis U.S. LLC)